Cargando…
OR33-5 Low Systemic Levels of Segesterone Acetate are Required to Inhibit Ovulation in Women
A one-year segesterone acetate (SA)/ethinyl estradiol (EE) contraceptive vaginal system (CVS; Annovera™) used to prevent pregnancy in women of reproductive age, was recently approved by the FDA (August 2018). Efficacy (Pearl Index of 2.98) and safety of the CVS were demonstrated in two phase 3, open...
Autores principales: | Archer, David, Sitruk-Ware, Regine, Mirkin, Sebastian, Brache, Vivian, Merkatz, Ruth, Kumar, Narender |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554891/ http://dx.doi.org/10.1210/js.2019-OR33-5 |
Ejemplares similares
-
SAT-219 A Novel 1-Year Contraceptive Vaginal System Delivering Segesterone Acetate and Ethinyl Estradiol: Effects on Lipids and other Hepatic Proteins
por: Archer, David, et al.
Publicado: (2019) -
SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
por: Liu, James H, et al.
Publicado: (2020) -
Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials
por: Archer, David F, et al.
Publicado: (2019) -
SAT-222 Hormone Responses Associated with Letrozole Ovulation Induction in Anovulatory Women with PCOS
por: Hadnott, Tracy, et al.
Publicado: (2019) -
FRI436 Design Of An International Male Contraceptive Efficacy Trial Using A Self-administered Daily Topical Gel Containing Testosterone And Nestorone™
por: Page, Stephanie T, et al.
Publicado: (2023)